
#PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 integrityce.com/TBT2025
🧐 Your patient w/ localized MSI-H CRC achieves a cCR after 12 mo of pembrolizumab and opts for organ-sparing surveillance. Which counseling point is most important regarding immune-related AEs in this setting❓
English



